Nav: Home

Milestone reached in new leukemia drug

November 19, 2019

Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute (DFCI), have developed a new therapy that extended the survival of mice with acute myeloid leukemia.

The scientists are the first to demonstrate the anti-cancer effect of blocking the Salt-Inducible Kinase 3 (SIK3) pathway in leukemia using YKL-05-099, a drug developed within the lab of Nathanael Gray at DFCI. SIK3 is a kinase that controls cell division and survival of leukemia cells. Blocking SIK3 prevents leukemia cells from growing.

"Our experiments validate that pharmacological blockade of SIK3 is well-tolerated and extends the survival of leukemic mice," said CSHL Professor Christopher Vakoc, who co-led the study with Kimberley Stegmaier at DFCI. Yusuke Tarumoto, a former postdoctoral researcher in Vakoc's lab, and Shan Lu of Stegmaier's lab are the co-first authors of the paper. Dr. Tarumoto is now a professor at Kyoto University. The team's findings are published in the journal Blood.

Vakoc refers to this type of leukemia treatment as epigenetic therapy, which can change gene activity within the cancer cell. "Because epigenetics is a cellular system that is malleable and dynamic, it's something that we can modulate with drugs," he said. "Developing epigenetic cancer therapies is the core mission of my lab, with SIK3 inhibition in leukemia being our most recently developed strategy."

In 2018, the Vakoc lab used CRISPR genetic screening to identify the SIK3 kinase as a non-obvious leukemia drug target.

"It's an under-studied signaling molecule in the pathogenesis of cancer because it's not mutated in cancer," Vakoc said.

The subtype of leukemia the researchers focused on, MLL, is an aggressive form of cancer that occurs in infants and can be caused by an abnormal rearrangement of chromosomes, which is known as an MLL translocation. "We discovered SIK3 has a very important role in the MLL translocation positive subtype of leukemia," Vakoc said.

The most important finding in this study is in revealing a drug development strategy for treating MLL leukemia.

The new compound created by the team to target SIK3 reprograms a transcription factor, which is a protein that can help turn specific genes on or off by binding to DNA. Vakoc's lab has been at the forefront of trying to reprogram transcription factors in cancer therapy.

"It's widely considered that this is impossible to do," he said. "Our lab wants to challenge that idea."

The study also helped researchers gauge the side effects of the drug. After using YKL-05-099 to suppress SIK3 in mice for a month, the researchers observed the drug to be well-tolerated, not causing any weight loss or significant changes to the animal's normal blood production.

"We took a basic science idea that we published in a paper last year and now we've shown that it may have some usefulness in the clinic," said Vakoc. "This new study advances our fundamental science towards clinical application, and it's a very important milestone in that process."
-end-


Cold Spring Harbor Laboratory

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Insomnia Line
Coronasomnia is a not-so-surprising side-effect of the global pandemic. More and more of us are having trouble falling asleep. We wanted to find a way to get inside that nighttime world, to see why people are awake and what they are thinking about. So what'd Radiolab decide to do?  Open up the phone lines and talk to you. We created an insomnia hotline and on this week's experimental episode, we stayed up all night, taking hundreds of calls, spilling secrets, and at long last, watching the sunrise peek through.   This episode was produced by Lulu Miller with Rachael Cusick, Tracie Hunte, Tobin Low, Sarah Qari, Molly Webster, Pat Walters, Shima Oliaee, and Jonny Moens. Want more Radiolab in your life? Sign up for our newsletter! We share our latest favorites: articles, tv shows, funny Youtube videos, chocolate chip cookie recipes, and more. Support Radiolab by becoming a member today at Radiolab.org/donate.